Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02267915 | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT(MAN2) | unknown | Phase 2 | 36 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma(MUKeleven) | unknown | Phase 1 | 4 | University of LeedsOTHER | 1 |
| Jan 22, 2020 |
| clinicaltrials |
| NCT03847727 | Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia | unknown | — | 112 | Pirogov Russian National Research Medical UniversityOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00505999 | Etiology of Multiple Myeloma: A Case-Control Study | unknown | — | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04212858 | Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma | unknown | N/A | 100 | Assiut UniversityOTHER | 0 | Dec 30, 2019 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT04194931 | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT03908138 | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | unknown | Phase 4 | 120 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 29, 2019 | clinicaltrials |
| NCT03110640 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT03702088 | Place of the Hevylite Test in the Evaluation of MRD in Myeloma | unknown | — | 124 | University Hospital, MontpellierOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04122092 | Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma(EUCADD) | unknown | — | 100 | Shanghai Changzheng HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04162119 | Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04156178 | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156243 | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04154228 | Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI | unknown | N/A | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Nov 6, 2019 | clinicaltrials |
| NCT04026100 | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 1 | 9 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02387879 | A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR | unknown | — | 500 | CelgeneINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02060656 | Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)(LEGEND) | unknown | Phase 2 | 92 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03618602 | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients | unknown | Phase 1 | 30 | Shanghai Theorion Pharmaceutical Co Ltd.INDUSTRY | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04094051 | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice | unknown | — | 580 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT04065308 | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma(Dara_DCEP) | unknown | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT04063189 | Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | unknown | Phase 2 | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04048395 | Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea(FLPOD24) | unknown | — | 80 | Samsung Medical CenterOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03715296 | Lenalidomide Based Immunotherapy in the Treatment of DLBCL | unknown | — | 200 | Ruijin HospitalOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03715309 | R2 in the Treatment of Follicular Lymphoma | unknown | Phase 2 | 115 | Ruijin HospitalOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03815383 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 12 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04008888 | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients | unknown | N/A | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04004338 | Carfilzomib in Combination for the Treatment of RR MM | unknown | — | 300 | Black Sea Hematology AssociationOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT02976272 | Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple(SENSIB) | unknown | — | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 1, 2019 | clinicaltrials |
| NCT03999697 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02954445 | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03992170 | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive(DART4MM) | unknown | Phase 2 | 50 | Azienda Ospedaliera Universitaria SeneseOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03931421 | B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03971565 | Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia(LLC) | unknown | — | 47 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03777085 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 3 | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2019 | clinicaltrials |
| NCT03751293 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03588598 | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | unknown | Phase 1 | 40 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2020source: clinicaltrials